Federal Pharmaceutical (03933.HK) receives $13.5 million milestone payment from Novo Nordisk for exclusive licensing agreement of UBT251.

Wise Finance APP News, Federal Pharmaceutical (03933.HK) announced that on July 15, 2026, Federal Biotechnology has received a milestone payment of 13.5 million US dollars (excluding Danish prepayment tax) from Novo Nordisk for UBT251 Injection for overweight or obesity indication in the global Phase I clinical trial.